



Overview of ViiV Healthcare Access & Care Programmes

John C. Pottage, Jr., M.D.

Access and Care Overview

Access: Scale up the numbers of people receiving ARV treatment through:

1. Non-for-profit pricing
2. Voluntary Licences, Royalty Free
3. Preferential Pricing



Care: Access to Medicines is underpinned by:

1. Positive Action
2. £50 million Positive Action for Children Fund
3. £10 million R&D project to deliver new paediatric FDC and formulations



Voluntary Licence Policy

1. Royalty Free Voluntary Licence Policy:

- Includes entire portfolio
- Extends to all least developed countries, low income countries and sub-Saharan Africa – covering 75% of people living with HIV
- 14 voluntary licences for ARVs.

2. Not-for-Profit Pricing Policy:

- Not for profit pricing available for ViiV produced ARVs in addition to voluntary licenses.

3. Preferential Pricing Policy:

In middle income countries,

- flexible pricing policy factoring in GDP and the impact of the epidemic in each country
- case-by-case basis, taking into account local need and context – including, for example building local manufacturing and marketing partnerships, facilitating technology transfer.

Supply of Combivir and Epivir tablets through licensees

Number of tablets (million)

2011*	717
2010	594
2009	358
2008	279
2007	183

■ ViiV Healthcare licensees
■ GSK licensees

* 2011 data include additional licensees however comparable 2010 data are not available.

Data should be considered a conservative estimate of use. All licensees are not captured in the data and data do not include paediatric formulations such as syrup. ViiV Healthcare are also aware of significant use of zidovudine and lamivudine in generic fixed dose combinations.

Medicines Patent Pool Voluntary Licence

1. Voluntary Licence agreement with the MPPF to increase access to HIV medicines for children
2. Licence for ABC containing FDCs and Formulations for treatment of paediatric HIV
3. 118 countries representing 98.7% of all children living with HIV
4. Commitment that current pipeline products for paediatric HIV treatment will be eligible to be licensed to the MPPF for the same 118 countries upon SRA approval
5. MOU collaborative elements in the announcement – ‘Catalytic Interventions’
 - Technology transfer including ABC/3TC dispersible
 - Access to data on medicine quality and efficacy
 - Planned partnerships with 3rd party stakeholders

Positive Action

When Positive Action was created in **1992** it was the **first pharmaceutical company program of its kind to support communities affected by HIV and AIDS.**

ViiV Healthcare is proud to support projects that:

- ✓ Enable grassroots community action
- ✓ Reach marginalized populations
- ✓ Tackle stigma & discrimination and reduce violence against at risk populations



During 2010-12 Positive Action worked with nearly **20 partners to support programs in over 50 countries.**



Paediatric Seed Fund

The £10 million fund supports partnerships with organisations that focus on the evidence base for paediatric care and treatment, the research and development of paediatric fixed-dose combination (FDC) products, and formulations for the treatment of infants and children living with HIV.

Paediatric Seed Fund Partners are: Clinton Health Access Initiative (CHAI), International AIDS Society (CIPHER), Elizabeth Glaser Pediatric Aids Foundation, Mater Misericordiae University and JUSTRI